You are here
Migraine Market 2019 Global Industry Size, Share, SWOT Analysis, Development Pipeline, Top Companies, Forecast to 2022
Global Migraine market information, by types (Episodic and Chronic), by treatment type (Preventive and Abortive), by drug class (Triptans, Ergots, and Others) - Forecast to 2022
Migraine Market Analysis
The global migraine market is predicted to grow at a notable CAGR over the forecast period (2013-2022), as per the latest Market Research Future (MRFR) report. Migraine is a common neurological condition which can cause multiple symptoms. Debilitating, intense headaches characterize this condition. Symptoms include sensitivity to sound and light, tingling or numbness, difficulty speaking, vomiting, and nausea. Often migraines run in families and affect every age.
Migraine is common in women compared to men, chiefly on account of the fluctuations that take place in the hormones. It is characterized into two types, migraine without aura or common migraines and migraine with aura called classical migraines. Usually, aura includes visual symptoms such as seeing flashes, shapes, or seeing lines. Often people may lose their vision for some time. Besides, they may also feel a tingling sensation in their legs and arms. The severity and symptoms can differ by attack, person, and over time.
Various factors are propelling the migraine market growth. These factors, as stated by the MRFR report, include rising adoption of novel drug classes, high unmet needs, the launch of CGRP (calcitonin gene-related peptide), increase in disease prevalence, and lifestyle changes. Additional factors pushing market growth include demand for hormonal medications, rising health expenditure, increasing female population, increasing prevalence of migraine, increasing cigarette consumption, and accelerating economic growth.
On the contrary, side effects related to migraine drugs may hamper the migraine market growth over the forecast period.
Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/2381
Migraine Market Segmentation
The Market Research Future report provides a wide segmental analysis of the migraine market based on drug class, treatment types, and types.
Based on type, the migraine market is segmented into chronic and episodic.
Based on drugs, the migraine market is segmented into ergots, triptans, and others.
Based on treatment types, the migraine market is segmented into abortive and preventive.
Migraine Market Regional Analysis
Based on the region, the migraine market report covers the latest trends and growth opportunities across Europe, Asia Pacific (APAC), North America, and the Rest of the World (RoW). Of these, North America will spearhead the market over the forecast period. The US is the key contributor in this region with more than 37 million suffering from migraine in the US alone. Besides, the other factors contributing to the market growth in this region include the huge target population in the US, adoption of new therapeutics, and the launch of CGRP based therapies.
Migraine Market Key Players
Leading players profiled in the migraine market report include GlaxoSmithKline plc, AstraZeneca plc, OptiNose, Merck, Meda, Luitpold Pharmaceuticals, Kowa Pharmaceuticals America, Klaria, Johnson & Johnson, Pfizer, Inc., Eli Lilly and Company, Eisai Inc., Abbott Laboratories, Inc., Impax Laboratories, and Allergan, among others. Key players have acquired several strategies to strengthen their position and create a foothold in the market. These include partnerships, acquisitions, mergers, product innovation, and product launch, expansion, research, and development activities, among others.
August 2019: DW Healthcare Partners recently has acquired CEFALY Technology SPRL, the leading Belgian manufacturers of neuro-modulating medical devices used to prevent and treat migraines. The CEFALY device is applied externally on the forehead of the patient. It delivers electrical impulses to a vital component of the nervous system, the trigeminal nerve that is involved in almost every migraine. This is a one of a kind device that is CE mark certified, registered with the FDA, and with several years of active commercial usage. The company’s robust and strong clinical data has successfully established CEFALY as an immensely effective as well as a safe solution for preventing and alleviating acute migraine pain.
Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/migraine-market-2381
Market Research Future
+1 646 845 9312
The reports of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.